PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Valacyclovir

Drugs in development · updated 30 October 2026

Valacyclovir: clinical trials and development status

Other names and codes: Valtrex

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Valacyclovir is in 14 active clinical trials (recruiting or ongoing, phases I–III) for 11 diseases. The most advanced phase is III.

14Active trials
IIIMost advanced phase
11Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Valacyclovir and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Prostatic NeoplasmsIII5NCT01436968
Non-small-cell lung carcinomaIII1NCT07660094
Acute painII1NCT05266040
AdenocarcinomaII1NCT07332000
GlioblastomaI–II1NCT07346144
Head and neck neoplasmsII1NCT07363031
LeukemiaII1NCT05536349
Post-Acute COVID-19 SyndromeII1NCT07597902
StomatitisII1NCT07363031
Waldenstrom MacroglobulinemiaII1NCT00492050
Brain NeoplasmsI1NCT06914479

Everything on Valacyclovir

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch